Tarceva 150mg Tablet
Contain : Erlotinib
Packing : 1*30
Strength : 150mg and 100mg
Manufactured by : Roche
Tarceva (erlotinib)150 mg Tablet is a human EGFR (Epidermal Growth Factor Receptor) tyrosine kinase inhibitor. Active Mutation of Protein Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR-TK) lead to Tumor Growth and Metastasis. Tarceva (erlotinib)150 mg Tablet is inhibit tumor growth by binding with the Epidermal Growth Factor Receptor.
Clinical study of Tarceva (erlotinib)Tablet has been conducted in the following patient population.
- 1) Treatment of Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC) after failure of at least one prior chemotherapy regimen.
- 2) Tarceva (Erlotinib) As a maintenance treatment for locally advance or metastatic NSCLC whose disease has not progressed after four cycle of platinum based first-line therapy.
3) Tarceva (erlotinib)as as first line treatment for Locally Advanced , unresectable or metastatic Pancreatic cancer, In combination with gemcitabine.
Generic Tarceva is available as a Erlonat ( Erlotinib) 150mg From Natco.
Common Adverse reaction like Diarrhea, Rash, Acne, Pruritis, Mild to Moderate Vomiting, Nausea, Anorexia, Dry Skin, Mild or Moderate rashes , fever, has been seen with Tarceva (erlotinib)150 mg Tablets. / Erlonat (Erlotinib) Tablets.
Tarceva (erlotinib)150 mg Tablet treatment should be taken after the consult of your doctor, the dose of Tarceva (erlotinib)150 mg Tablet is once daily. You can take tablet one hour before food or two hour after food. If any adverse reaction occur please consult your doctor.
K M Healthcare Supplier of Tarceva worldwide.